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Background: Pharmaceutical expenditure is undergoing very high growth, and accounts for 30% of overall
healthcare expenditure in Spain. In this paper we present a prediction model for primary health care
pharmaceutical expenditure based on Clinical Risk Groups (CRG), a system that classifies individuals into mutually
exclusive categories and assigns each person to a severity level if s/he has a chronic health condition. This model
may be used to draw up budgets and control health spending.
Methods: Descriptive study, cross-sectional. The study used a database of 4,700,000 population, with the following
information: age, gender, assigned CRG group, chronic conditions and pharmaceutical expenditure. The predictive
model for pharmaceutical expenditure was developed using CRG with 9 core groups and estimated by means of
ordinary least squares (OLS). The weights obtained in the regression model were used to establish a case mix
system to assign a prospective budget to health districts.
Results: The risk adjustment tool proved to have an acceptable level of prediction (R2 ≥ 0.55) to explain
pharmaceutical expenditure. Significant differences were observed between the predictive budget using the model
developed and real spending in some health districts. For evaluation of pharmaceutical spending of pediatricians,
other models have to be established.
Conclusion: The model is a valid tool to implement rational measures of cost containment in pharmaceutical
expenditure, though it requires specific weights to adjust and forecast budgets.
Keywords: Risk adjustment, Predictive models, Pharmaceutical expenditure, Chronic condition, Clinical Risk Groups,
Capitation paymentsBackground
The growth in pharmaceutical cost is a real problem in
health care sustainability [1]. This is due to a number of
factors: ageing of population, introduction of new med-
icines and changes in prescription practices and age-
related patient complexity. Furthermore, studies focusing
on a clear understanding of pharmaceutical consumption,
cost and morbidity patterns are needed to implement
effective cost control.
One of the widest used tools for cost control in health
expenditure is that of risk adjustment, used to make capi-
tation finance systems. These can be found worldwide for* Correspondence: dvivas@upvnet.upv.es
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article, unless otherwise stated.both clinical and pharmaceutical management. In health
systems where competition between insurance companies
exists, such as USA and Germany, capitation attempts
to avoid adverse risk selection. In other countries with
comprehensive national health systems, such as UK and
Sweden, capitation is used for an equitable distribution
of resources [2].
Early approaches to adjustment of health expenditure
were based on demographic variables alone. However, the
introduction of other clinical variables related with popula-
tion health statuses has improved this adjustment in several
countries.
The work of Mossey and Roos [3] was the starting point
for different studies that use disease related cost for risk
adjustment, using information from insurance companies.
The first diagnostic based models for forecasting healthCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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(Adjusted Average Per Capita Cost) [4] and DCG (Diag-
nostic Cost Groups) [5].
In the last 20 years, various studies have been carried
out on the use of cost indicators based on information
available from electronic records previously used by clin-
ical services. The three best known Diagnostic Based
Risk Adjustment Systems (DBRAS) are: Diagnostic Cost
Groups/Hierarchical Coexisting Conditions (DCG/HCC)
developed by Pope et al. [6,7], Adjusted Clinical Groups
(ACG) developed by Starfield et al. [8] and Weiner et al.
[9] at Johns Hopkins University in Baltimore and Clinical
Risk Groups (CRG) developed by Hughes et al. [10]. All
of these are based on the International Classification of
Disease, 9th Revision, Clinical Modification (ICD-9-CM),
the codes of which are recorded electronically. While the
DCG is based on cost, ACG and CRG were developed to
measure health statuses.
According to a study by Berlinguet, Preyra and Dean
[11], the CRG have greater clinical relevance while offer-
ing a predictive power similar to the other two systems
(ACG and DCG/HCC).
Another important classification system is the Chronic
Disease Score (CDS), developed by Von Korff et al. [12]
using pharmaceutical consumption to identify chronic
conditions of patients. This uses pharmacy databases to
estimate disease prevalence in the absence of diagnostic
information. Moreover, these databases have the advan-
tage of generally being complete, precise and reliable,
while codification of diagnostics may only register those
conditions treated during a clinical visit or hospital stay
and, as such, not reflect other important chronic condi-
tions [13].
Various later studies have analysed the validity of the
four health state indicators above, perfecting them and
adapting them to each specific situation. Thus, different
models of pharmaceutical expenditure were obtained from
the CDS [14-19], DCG/HCC system [20,21].
Although the ACG [22,23], and CRG systems were
developed to measure health status, their validity in
explaining pharmaceutical expenditure has also been
demonstrated [24-26].
In the United States, Medicare uses the developed DCG/
HCC model. In 2006 they implemented the model, CMS
(Centres for Medicare and the Medicaid) prescription drug
hierarchical condition categories RxHCC [27]. For capita-
tion payments the CMS-HCC model [7], based only on
diagnostics, is used. The use of differentiated models for
capitation and medicine payments is based on the findings
of Zhao et al. [28], who give better predictive power for
future prescription drug costs for mixed models that
combine diagnostic and drug use data.
Other countries have their own system, such as that in
Germany, where a morbidity based risk adjustment wasintroduced in 2009, embedded in a broader reform of
the statutory health insurance system. The new formula
covers 80 “severe” or “costly and chronic” diseases struc-
tured in a system of hierarchical groups [29].
The CRG system in Spain was first implemented in the
Baix Empordà Health Service (Serveis de Salut del BaixEm-
pordà) [30], and projects are under way in the Autonomous
Communities of Catalonia and Madrid. Other Autonomous
Communities like the Pais Vasco [31] and some health
centres in the Balearics [32] have opted for ACG. Regardless
of the system used, all these suppose a significant advance
on previous systems based on epidemiological variables
[33] or prescriptions [14].
Over recent years, the Valencian Community (VC)
(East coast of Spain) has been interested in adapting
health expenditure by linking it with population mor-
bidity. Firstly, the General Directorate of Pharmaceut-
ical and Health Products (DGFPS) of the Valencian
Health Department designed a standardised amount in-
dicator [34] which offered primary health care pharma-
ceutical expenditure data per patient covered in a year.
This allowed the standardisation of the population
based on two categories: patients covered by the health
system who have the right to free medication (funda-
mentally pensioners) and patients covered by the sys-
tem who must pay part of the cost of the medication
from the pharmacy. According to this, in 2011 primary
health care pharmaceutical expenditure per standardised
patient was 338 Euros, compared with the 275 Euros ob-
tained without standardisation.
This indicator supposes an improvement regarding
precision of results and was achieved thanks to the de-
velopment of appropriate information systems and more
specifically that of the primary health care electronic
health record [35].
Vivas et al. [36] developed a model using Anatomical
Therapeutic Chemical Classification (ATC) from elec-
tronic prescriptions drug data to explain pharmaceutical
expenditure at a local level.
Since 2010, the DGFPS has been developing a system
of patient classification in the VC based on CRGs, which
allows stratification of patients according to morbidity.
The differences between the use of data from prescrip-
tions and diagnostics that have been observed in the
DCG models do not affect the models based on CRG.
The predictive power of CRG for future pharmaceut-
ical expenditure has been demonstrated in three prior
studies [24-26].
The goal of this work is to obtain a concurrent model
of primary health care pharmaceutical expenditure for the
entire region using CRGs. From this model we obtain
weights for primary health care pharmaceutical expend-
iture per inhabitant and year based on the CRG, which
may then be used to draw up budgets for the following
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tricts of VC.
Methods
Data
The data was taken from the Population Information
System’s (PIS) database of all patients registered and
assigned to one of the 24 health districts in the VC, a re-
gion of 4.7 million inhabitants for the period 1st Jan to 31st
Dec for 2012 and 2013. Although the initial number of pa-
tients was 5.2 million, 400,000 were discarded as non-
residents with a stay of less than one month, leaving a
total of 4.7 million for analysis. All information was made
anonymous according to data protection regulations and
our study was approved by the Behavioural Research Eth-
ics Board at the Generalitat Valenciana.
For each patient we obtained the following information.
Socio-demographic data: patient anonymisation code,
age, sex, health centre, area, health district, PIS state
(active/inactive) and pharmacy status (with or without
co-payment). Usage data needed for the CRG grouper
were: number of contacts in primary health care, num-
ber of hospital admissions, and days in hospital per ad-
mission (main diagnosis, coded according to ICD-9-
CM). CRG data: CRG Base, ACRG1, ACRG2, ACRG3
(Table 1). Pharmaceutical cost data: cost of medicines
according to the invoicing nomenclature of the Minis-
try for Health, Social Policies and Equality. These costs
refer to the pharmaceutical expenditure in primary
health care centres, which means the total cost is not
included for health statuses 8 and 9, given that the ma-
jority of these medicines are provided by the hospitals.
Data sources
Data for the study was obtained from the electronic health
record for primary health care (SIA) and the Minimum
Data Set (MDS) of hospitals. Data for primary health
care pharmaceutical expenditure was obtained from the
prescription module of the Pharmaceutical Provision
Manager, GAIA. The full amount of each prescription
expended during the study period was accounted for.
CRG calculation
To obtain the CRG we used 3 M™ Clinical Risk Grouping
Software v.1.4. CRGs capture the resource utilization of all
inpatient and ambulatory encounters. The groups identify
individuals with multiple chronic co-morbid conditions
and explicitly specify the severity of illness for each indi-
vidual. The CRG system maps each diagnosis to one of
1,079 CRG groups that are similar in terms of relative se-
verity, persistence, or recurrence, and health care resourceexpectations. CRGs, at the discretion of the user, can then
be aggregated in order to reduce the number of groups.
There are three tiers of aggregation. These are identified
as ACRG1, ACRG2, and ACRG3 (Table 1). Each one pro-
gressively reduces the number of groups while maintain-
ing, albeit with some adjustment, severity leveling. In
the designed models we use 8 dummy variables - one
for each core health status - plus 6 dummy variables for
severity levels.
Statistical analysis
With the data for 2012, concurrent regression models
were made using the total pharmaceutical expenditure
by patient and year (C) as dependent variable. As C was
not normally distributed, C is ln-transformed as a better
approach to its normal distribution [37].
As 420,000 patients (8%) had cost 0, which results in
ln -inf, the final dependent variable was considered to
be C + 1, resulting in all cost values < 1 having a posi-
tive Ln value. Prediction from these models must then
be retransformed by subtracting -1, to obtain estimates
on the original scale.
Six models were made using the 2012 data, combining
the following independent variables in each model:
(i) age and sex (1 male and 0 female);
(ii)age, sex, and 8 CRG core health statuses;
(iii)8 CRG core health statuses alone;
(iv) 8 CRG core health statuses, only for the paediatric
cohort;
(v)8 CRG core health statuses excluding paediatrics
cohort;
(vi) 8 CRG core health statuses, 6 severity levels, age
and sex, excluding paediatric population.
In all models except (i), the healthy group (Health Status
1) was the control variable necessary in the regression
model. Models (i), (ii) and (vi) were designed to observe if
there is any difference between age and sex groups.
The models were estimated by means of ordinary least
squares (OLS). The goodness of fit was determined through
the corrected R2 value and the F Snedecor, mean squared
error, and for each of β coefficients t-Student values were
obtained to determine the level of significance. The as-
sumptions of normality, homoscedasticity and linearity
were considered. Split analysis validation to avoid over-
fitting was carried out. We used a random sample of
70% of the study subjects for model development and
30% for model validation.
The weight of each health status according to the
pharmaceutical expenditure for this status was obtained
by retransforming the predicted ln expenditures back into
nominal using the smearing estimate provided by Duan
(1983) [38]. With this nonparametric retransformation the
Table 1 Population (N), annual pharmaceutical expenditure in Euros and age by CRG core health status and severity
level (ACRG3) 2012
ACGR3 N %N Average
expenditure
Total
expenditure
Average
age
St. Dv.
age
1. Healthy
10 Healthy 1,633,686 35.10% 42.63 69,644,034 28.56 19.05
11 Healthy Non-User 784,168 16.85% 0.00 0 36.21 16.99
12 Delivery without Other Significant Illness 28,921 0.62% 49.30 1,425,805 30.56 8.41
14 Pregnancy without Other Significant Illness 19,451 0.42% 35.92 698,680 31.26 6.93
15 Evidence of Significant Chronic or Acute
Diagnosis without Other Significant Illness
152,488 3.28% 190.76 29,088,611 40.35 23.00
2. History of significant acute disease
20 History Of Significant Acute Disease 193,19 4.15% 95.96 1,853,851 33.23 19.65
22 Delivery with History of Significant Acute Illness 15,875 0.34% 209.51 3,325,971 33.87 10.84
24 Pregnancy with History of Significant Acute Illness 7,108 0.15% 64.70 459,888 31.83 5.99
25 Evidence of Significant Chronic or Acute
Diagnosis with History of Significant Acute Illness
44,836 0.96% 166.72 7,475,058 38.06 21.98
3. Single minor chronic disease
31 Single Minor Chronic Disease Level - 1 403,148 8.66% 190.25 76,698,907 45.58 18.58
32 Single Minor Chronic Disease Level - 2 41,173 0.88% 258.48 10,642,397 43.19 19.23
4. Minor chronic disease in multiple Organ Systems
41 Minor Chronic Disease In Multiple Organ Systems Level - 1 90,903 1.95% 339.85 30,893,385 55.72 15.69
42 Minor Chronic Disease In Multiple Organ Systems Level - 2 25,3 0.54% 515.28 130,366 61.58 13.52
43 Minor Chronic Disease In Multiple Organ Systems Level - 3 34,801 0.75% 520.02 18,097,216 57.91 15.38
44 Minor Chronic Disease In Multiple Organ Systems Level - 4 5,204 0.11% 704.89 3,668,248 59.07 14.99
5. Single dominant or moderate chronic disease
51 Single Dominant Or Moderate Chronic Disease Level - 1 484,232 10.40% 528.68 256,003,774 54.76 21.09
52 Single Dominant Or Moderate Chronic Disease Level - 2 135,731 2.92% 739.94 100,432,796 54.37 22.66
53 Single Dominant Or Moderate Chronic Disease Level - 3 39,795 0.86% 1108.05 44,094,850 59.30 19.73
54 Single Dominant Or Moderate Chronic Disease Level - 4 5,133 0.11% 1061.65 5,449,449 63.83 21.39
55 Single Dominant Or Moderate Chronic Disease Level - 5 9,556 0.21% 1348.04 12,881,870 66.70 17.46
56 Single Dominant Or Moderate Chronic Disease Level - 6 761 0.02% 1961.34 1,492,580 51.56 18.79
6. Chronic disease in 2 or more Organ Systems
61 Significant Chronic Disease In Multiple Organ Systems Level - 1 217,363 4.67% 994.26 216,115,336 66.93 15.42
62 Significant Chronic Disease In Multiple Organ Systems Level - 2 93,125 2.00% 1362.09 126,844,631 69.14 14.57
63 Significant Chronic Disease In Multiple Organ Systems Level - 3 62,212 1.34% 1567.73 97,531,619 70.90 13.95
64 Significant Chronic Disease In Multiple Organ Systems Level - 4 40,647 0.87% 1835.01 74,587,651 72.87 13.26
65 Significant Chronic Disease In Multiple Organ Systems Level - 5 19,282 0.41% 2074.03 39,991,446 75.06 13.02
66 Significant Chronic Disease In Multiple Organ Systems Level - 6 2,259 0.05% 2087.73 4,716,182 75.24 13.40
7. Dominant Chronic Disease in 3 or more Organ Systems
71 Dominant Chronic Disease In Three Or More Organ Systems Level - 1 7,202 0.15% 1861.56 13,406,955 73.70 10.35
72 Dominant Chronic Disease In Three Or More Organ Systems Level - 2 5,913 0.13% 2159.61 12,769,774 74.88 10.54
73 Dominant Chronic Disease In Three Or More Organ Systems Level - 3 12,577 0.27% 2420.64 30,444,389 76.04 10.33
74 Dominant Chronic Disease In Three Or More Organ Systems Level - 4 3,587 0.08% 2677.64 9,604,695 77.33 9.95
75 Dominant Chronic Disease In Three Or More Organ Systems Level - 5 2,694 0.06% 2784.93 7,502,601 77.07 10.08
76 Dominant Chronic Disease In Three Or More Organ Systems Level - 6 1,076 0.02% 2528.73 2,720,913 76.05 10.06
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Table 1 Population (N), annual pharmaceutical expenditure in Euros and age by CRG core health status and severity
level (ACRG3) 2012 (Continued)
ACGR3 N %N Average
expenditure
Total
expenditure
Average
age
St. Dv.
age
8. Dominant and Metastatic Malignancies
81 Dominant, Metastatic, And Complicated Malignancies Level - 1 1,677 0.04% 800.04 1,341,667 61.41 16.28
82 Dominant, Metastatic, And Complicated Malignancies Level - 2 5,692 0.12% 1223.61 6,964,788 62.59 16.67
83 Dominant, Metastatic, And Complicated Malignancies Level - 3 6,419 0.14% 1649.05 10,585,252 66.99 14.72
84 Dominant, Metastatic, And Complicated Malignancies Level - 4 4,878 0.10% 2021.68 9,861,755 69.61 13.66
85 Dominant, Metastatic, And Complicated Malignancies Level - 5 1,389 0.03% 2131.74 2,960,987 70.86 12.19
9. Catastrophic conditions
91 Catastrophic Conditions Level - 1 1,895 0.04% 1632.93 3,094,402 44.83 22.15
92 Catastrophic Conditions Level - 2 3,647 0.08% 1164.40 4,246,567 46.30 16.97
93 Catastrophic Conditions Level - 3 1,857 0.04% 1944.29 3,610,547 53.82 19.86
94 Catastrophic Conditions Level - 4 2,02 0.04% 1949.96 393,892 52.68 16.77
95 Catastrophic Conditions Level - 5 976 0.02% 2244.09 2,190,232 63.49 16.67
96 Catastrophic Conditions Level - 6 515 0.01% 2368.46 1,219,757 65.04 16.37
Total 4,654,362 100% 298.71 1,301,898,793 41.32 23.07
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this smearing estimate is:
E Cð Þ ¼ E e xi βð Þε
 
¼ 1
n
Xn
i¼1
e xi βð Þþε1
 
¼ e xi βð Þ
  1
n
Xn
i¼1
eε1ð Þ
 !
¼ e xi βð Þ
 
γ ð1Þ
Where:
ε= the residual errors.
n = number of observations.
With model iii selected to predict the cost, we estab-
lished a case mix (CM) system based on the weights of
each of the health statuses. Thus, it is possible to calcu-
late the CM for the region and each health district and
compare the allocated budget with real expenditure.
The equation for CMj calculation for each health district
j is:
CMj ¼
X9
i¼1Nij WiX9
i¼1Nij
ð2Þ
Where,
Nij = Number of population of group i in the health
district j.
Wi =Weight of each i core health status group.The process used for obtaining a predictive budget by
health district was the following: Firstly, the weights
were calculated for 2012 using the regression model with
real data to establish the relative consumption for each
CRG. Through the expression (2) the CM is calculated.
The Health Authority then established an overall budget
for pharmaceutical expenditure for 2013, partly by
taking into account the prior year’s expenditure. Ap-
plying the weights, we calculated the number of ad-
justed patients, and divided the overall budget by this
number, obtaining the standard price of an adjusted
patient. This allows us to give a budget to each doc-
tor or district according to the number of adjusted
patients they have.
The model weights are recalibrated annually to intro-
duce possible changes relating to health status, price
changes and clinical practice. A cap is established, how-
ever, for maximum target budget. That is, a cost per pa-
tient adjusted by morbidity is set each year which is used
to establish the budget.Results
Patient stratification and pharmaceutical expenditure
Table 1 shows the number of patients, classified into each
of the nine CRG core health statuses, percentage of pa-
tients and the average cost for the year 2012. In the graph
for this data (Figure 1) it can be clearly seen how each
strata of the population is related to the pharmaceutical
expenditure. Health Status 6 (chronic disease in 2 or
more organ systems) represents 48% of total primary
0%
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Number of patients 
by Health Status
Pharmaceutical 
expenditure by 
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9. Catastrophic conditions
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organ systems
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Figure 1 Stratification of patients by core health status and pharmaceutical expenditure in 2012. Shows a graph for the number of
patients, classified into each of the nine CRG core health statuses, and the average cost in this period. In the graph for this data it can be clearly
seen how each strata of the population is related to the pharmaceutical expenditure.
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representing 11% of population.
Health status 5 (single dominant or moderate chronic
disease) represents 26.4% of total primary health care
pharmaceutical expenditure while only representing 15.1%
of population. These two statuses together account 74.4%
of total expenditure (Figure 1).
Regression models
In Table 2 we show the model coefficients and other
statistics. Of the proposed models, model (vi) achieved
the best fit, with an R2 of 60.3%.
Furthermore, within the Spanish health system it is
important to analyse the pharmaceutical expenditure for
patients under 14, as these patients are attended by paedi-
atricians in primary health care. Applying the CRG model
(iv) to this cohort, we found a very low level of explan-
ation, 15.8%. Therefore a special predictive model must be
developed for these patients.
In spite of models (ii), (v) and (vi) being better, we have
taken the coefficients from model (iii), the R2 of which
is 55% for reasons of operational and practical use and
understanding by clinical users.
For the CM system implemented, relative weights were
established by retransforming the coefficient for each
health state through the smearing estimator and adding
the value of 1 as presented in Table 3. The result of the
smearing estimator (γ), the mean of the anti-ln of the re-
siduals, was 1.693 (expression 1).
It should be noted that for groups 8 and 9 we obtained
lower weights than given by the original CRG. This is
due to patients in these groups principally using hospital
dispensaries, while our study drew data from primary
health care only. These patients suffer from malignanciesand catastrophic diseases such as renal failure or organ
transplants.
Analysis by health district
Figure 2 shows the number of patients assigned to each
health district, grouped in health statuses. The line repre-
sents the CM in the health departments, calculated as the
summation of equivalent patients divided by real patients
in each health district, expression (2).
Figure 3 shows the relation between predicted ex-
penditure according to CM and real pharmaceutical
expenditure in primary care for each health district. 13
health districts have spent less than was estimated by
the proposed model considering the health status of
patients assigned to them, and 11 have incurred higher
costs than predicted. This means that with the same
equivalent patients, some departments generate higher
outpatient pharmaceutical spending than others and
some health departments are managing pharmaceutical
spending better than others (Table 4).
Discussion
The study results show the basis for a pharmaceutical
management model designed to improve efficiency in the
use of medicines and allocation of budgets. The main
innovation is the linking of pharmaceutical expenditure to
patient morbidity, a factor not introduced until now in the
majority of European health systems.
Discussion points may be centred around three as-
pects: the reliability of the classification system, the
predictive capacity of the developed model, and prac-
tical utility.
The reliability of CRGs with respect to correct patient
stratification depends on the appropriate inclusion of
Table 2 Results of different predictive models for pharmaceutical expenditure per year and patient (C) in Euros 2012
Model i
age & sex
Model ii
CRG core
health status,
age & sex
Model iii
CRG core
health status
Model iv
CRG core
health status
Model v
CRG core
health status
Model vi
CRG core health
status, severity
level, age & sex
Variables Total population Total population Total population Under or equal 14 14 PLUS 14 PLUS
Constant 1.159 1.391 1.736 1.865 1.697 .906
Age .057 .016 .026
Sex -.461 -.324 -.388
Health status 2 1.751 1.816 1.262 1.955 1.873
Health status 3 2.179 2.440 1.548 2.537 2.214
Health status 4 3.201 3.691 2.134 3.743 2.951
Health status 5 3.399 3.799 2.119 3.954 3.291
Health status 6 4.352 4.992 3.120 5.048 3.946
Health status 7 5.055 5.760 3.920 5.801 4.400
Health status 8 4.325 4.870 1.891 4.946 3.713
Health status 9 4.217 4.493 3.129 4.608 3.785
Severity level 2 .406
Severity level 3 .613
Severity level 4 .701
Severity level 5 .823
Severity level 6 .878
F 883600.05 613728.44 711221.29 17380.11 650280.64 396142.59
N 4,654,362 4,654,362 4,654,362 739,525 3,914,837 3,914,837
R2 0.275 0.569 0.550 0.158 0.571 0.603
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One of the indicators for evaluating this is the percent-
age of healthy patients, both users and non-users. The
results presented here have greatly improved with re-
spect to stratifications undertaken in the trial period and
those presented by other authors. The deficiencies in the
initial diagnostics code gave this group as being 60% of
the population, whereas with correct coding the value is
52%, representing the real proportion (34% healthy usersTable 3 Calculation for weights by CRG core health status fro
Core health status Ln (C
1. Healthy 1.
2. History of significant acute disease 3.
3. Single minor chronic disease 4.
4. Minor chronic disease in multiple organ systems 5.
5. Single dominant or moderate chronic disease 5.
6. Chronic disease in 2 or more Organ Systems 6.
7. Dominant Chronic Disease in 3 or more Organ Systems 7.
8. Dominant and Metastasic Malignances 6.
9. Catastrophic conditions 6.
(a) = Ln (C + 1).
(b) = (1.693 ea)-1.
(c) = bi/b1.and 16% non-users). This indicates a substantial im-
provement in the codification. Other authors, using data
from 2008, give this status to 70% of the population [30].
The proposed model uses population stratification into
risk groups based on CRGs, but develops its own weights
for CRG core health statuses. If we compare the predictive
capacity of this model with others described in the bibliog-
raphy that use other patient classification systems, we see
that it reaches, at minimum, the same level of explanationm model 2012
+ 1) (a) Expenditure C (b) Standard weight (c)
736 8.607 1
552 58.068 6.75
176 109.242 12.69
427 384.212 44.64
535 427.851 49.71
728 1413.267 164.21
496 3048.575 354.21
606 1250.432 145.29
229 858.032 99.69
Figure 2 CRG core health status by health district and case mix 2012. Shows a stacked column chart, comparing the contribution
of each value to a total across categories of CRGs core health statuses for each health districts. The x axis of the chart shows the
health districts compared and the y axis represent a double scale with the case mix on the right and the n° of patient grouped by
CRG core health status on the left.
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based on patient classification using ATC [36] achieve an
R2 of 57%, the models based on ACG [23] 35.4%, and
those that use DxRx-PMs [39] 42.6%.
As the goal of our model is to assign predictive bud-
gets with an objective level of expenditure for the health
districts and primary health care physicians, it should beFigure 3 Pharmaceutical expenditure real and predicted by health di
predicted (x axis) pharmaceutical expenditure of each heath district.noted that the general model does not serve for the
population of under-14s attended by paediatricians. As
such, this is one of the weaknesses of a CRG based
model. This also occurs in the ACG system, as indi-
cated by Aguado et al. [23], who note that in children
there is greater variability among physicians and centres
not related to case-mix.strict 2013. Shows a scatter plot to display values for real (y axis) and
Table 4 Real and predicted pharmaceutical expenditure and case mix adjusted by health district in 2013
Health district Case mix (1) Real C (2) Predicted C (3) Population. N (4) Average real
C (5) = (2)/(4)
Average predicted
C (6) = (3)/(4)
Differences
(7) = (5)-(6)
1 35.29 22,404,536.70 24,714,441.39 87,448 256.20 282.62 -26.41
2 32.34 68,608,549.95 68,793,348.13 265,636 258.28 258.98 -0.70
3 35.94 47,720,043.15 51,816,313.29 180,051 265.04 287.79 -22.75
4 35.20 43,430,451.48 41,221,848.93 146,219 297.02 281.92 15.10
5 33.39 88,177,744.42 85,893,722.31 321,192 274.53 267.42 7.11
6 32.15 72,489,772.23 75,357,459.28 292,715 247.65 257.44 -9.80
7 36.18 49,825,584.93 52,580,973.57 181,468 274.57 289.75 -15.18
8 43.10 15,989,816.02 16,733,570.96 48,479 329.83 345.17 -15.34
9 34.48 99,701,853.24 93,549,589.70 338,770 294.31 276.14 18.16
10 34.22 97,918,781.79 93,218,916.90 340,151 287.87 274.05 13.82
11 34.43 66,559,137.30 68,259,770.67 247,529 268.89 275.76 -6.87
12 34.13 49,736,535.24 46,595,511.68 170,456 291.79 273.36 18.43
13 31.76 41,575,756.05 39,612,929.41 155,755 266.93 254.33 12.60
14 37.28 60,142,256.18 57,547,721.39 192,759 312.01 298.55 13.46
15 37.36 40,973,176.21 40,243,795.62 134,490 304.66 299.23 5.42
16 33.48 43,043,816.92 45,423,640.85 169,389 254.11 268.16 -14.05
17 33.97 52,476,085.67 54,889,413.61 201,780 260.07 272.03 -11.96
18 35.24 54,265,489.06 52,482,585.31 185,984 291.78 282.19 9.59
19 34.15 66,260,672.07 69,172,538.68 252,932 261.97 273.48 -11.51
20 34.54 39,467,859.22 42,750,213.31 154,533 255.40 276.64 -21.24
21 34.29 41,080,531.21 43,366,934.60 157,932 260.12 274.59 -14.48
22 35.09 44,150,450.69 44,686,006.13 159,031 277.62 280.99 -3.37
23 35.01 55,746,290.13 54,498,692.53 194,401 286.76 280.34 6.42
24 32.31 40,153,602.94 38,488,854.55 148,732 269.97 258.78 11.19
Total 34.38 1,301,898,792.80 1,301,898,792.80 4,727,832 275.37 275.37 0.00
(1) District case mix (CM).
(2) Annual real cost.
(3) Predictive expenditurehealth district = real expenditurevc CMhealth district Nhealth district/CMcvNvc.
(4) Health district total population.
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model, there are two other variables to consider in
pharmaceutical expenditure in budgetary adjustments:
the cost of the medicines and the goals of the adjust-
ment. Over recent years we have effectively seen drops
of around 7% in the price of medicines, driven by the
increase in the consumption of generics and the reduction
in prices from the Ministry for Health, Social Policies and
Equality. During the last three years there has been a de-
crease every month in the prices set by the Spanish Agency
for Medicines (Agencia Española de Medicamentos).
The other factor is the adjustment of pharmaceutical
expenditure made by the health authorities via the proto-
cols of rational use that prevent multiple medication of a
patient and the use of medicines not based on evidence,
especially in chronic pathologies such as hypercholesterol-
emia or osteoporosis. As such, in establishing expenditure
goals by district and doctor from the specific experiencefrom the VC for 2013, the forecast expenditure of the
model decreases by 15%.
We observed the need for advanced and efficient IT
development as a condition for the introduction of this
system. Firstly, for the stratification of patients using the
CRG system and then a further programme to commu-
nicate the classifications and predictions to the health
districts and health workers. The IT system developed
allows us to know the chronic diseases and co-morbidity
of the patients included in each health status. This is of
the greatest use when managing patients in programmes
for the most prevalent chronic diseases. The system is
linked to the EHR, making it possible to know all the
diagnoses, treatments, hospital stays, etc.
Conclusions
The developed model based on CRGs can be of great use
in managing the pharmaceutical spending in integrated
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(NHS). In future development hospital pharmaceutical
expenditure must be included to better explain the
weights of statuses 8 and 9.
The predictive power of the developed model is simi-
lar to other models based on diagnostics, validating its
use in managing primary health care pharmaceutical
expenditure.
The general case-mix model is not applicable for es-
tablishing expenditure goals for paediatrics, as the CRG
classification system is not valid for isolated patients of
under 14 years of age.
The predictive models must consider adjustments which
include variations in the price of medicines and rational-
isation measures in pharmaceutical expenditure, so as to
produce incentive-based targets.
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